Raymond James Financial
IMCR icon

Raymond James Financial’s Immunocore IMCR Stock Holding History

Raymond James Financial’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22
Closed -$690 – 5802
2025
Q2 		$690 Buy
+22
New +$683 ﹤0.01% 6628

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Raymond James Financial's IMCR Position: Q3 2025 in Review

Raymond James Financial sold out of Immunocore (IMCR) in Q3 2025, closing a stake of 22 shares — an estimated $690 sold.

Raymond James Financial first reported a position in IMCR in Q2 2025 and held it in 1 quarter. The position peaked at $690 in Q2 2025. 132 funds tracked by Wall St. Rank hold IMCR as of Q3 2025.

  • Raymond James Financial reported no remaining Immunocore position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 22 Immunocore shares in Q3 2025, an estimated $690.
  • Raymond James Financial first reported a position in Immunocore in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Immunocore position peaked at $690 in Q2 2025.
  • 132 funds tracked by Wall St. Rank held Immunocore as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.